RecruitingSolid Tumors, Adult
HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor
Eligible age
18+ yrs
Accepts
All genders
Locations
4 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a first-in-human, multicenter, open-label, phase I/Ⅱa clinical study of HMPL-A580 in participants with unresectable, advanced or metastatic solid tumors.
Sponsor: Hutchmed
You may qualify if…
- ✓ 1. Understood this study and are able to voluntarily sign the informed consent form (ICF);
- ✓ 2. Male or Female, Age ≥ 18 years;
- ✓ 3. Histological confirmed, unresectable, advanced or metastatic solid tumor
- ✓ 4. Participants must have at least one measurable lesion per Response Evaluation Criteria in Solid Tumors(RECIST) v1.1
- ✓ 5. Life expectancy ≥ 12 weeks
- ✓ 6. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1
You may not qualify if…
- ✕ 1. An established diagnosis of type 1 diabetes mellitus or uncontrolled type 2 diabetes mellitus
- ✕ 2. Use strong inhibitors of cytochrome P450 3A4 enzyme (CYP3A4), and inhibitors of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) within 5 elimination half-lives or 2 weeks (whichever is longer) before the first dose of study drug
- ✕ 3. Major surgery within 28 days prior to the first dose of study drug
- ✕ 4. Active infection requiring systemic treatment
- ✕ 5. Participant has received a live within 3 months before study enrollment
- ✕ 6. History of inflammatory gastrointestinal diseases
- ✕ 7. Known hypersensitivity to any component of HMPL-A580
- ✕ 8. Pregnant (positive pregnancy test) or lactating;
Where it's recruiting
Source: ClinicalTrials.gov · NCT07396584 · last updated 2026-09-18